The Improved Experience You’ve Been Waiting For!
Discover the refreshed menu, enjoy the custom dashboard, and make use of the powerful stock screener to enhance your investment approach.
Explore Now
Big Pharma Split Corp Class A (PRM:CA) Stock Forecast
Alert
Its only available to paid users.
N/A
Based on the Big Pharma Split Corp Class A stock forecast from 0 analysts, the average analyst target price for Big Pharma Split Corp Class A is not available over the next 12 months. Big Pharma Split Corp Class A’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Big Pharma Split Corp Class A is Slightly Bearish, which is based on 4 positive signals and 6 negative signals. At the last closing, Big Pharma Split Corp Class A’s stock price was CAD 14.97. Big Pharma Split Corp Class A’s stock price has changed by +4.18% over the past week, +5.05% over the past month and +1.77% over the last year.
No recent analyst target price found for Big Pharma Split Corp Class A
No recent average analyst rating found for Big Pharma Split Corp Class A
Company Overview Big Pharma Split Corp Class A
Big Pharma Split Corp is a closed ended equity mutual fund launched and managed by Harvest Portfolios Group Inc. It invests in the public equity markets across United States. The fund primarily invests in the Pharmaceutical sector. Big Pharma Split Corp was formed on September 15, 2017 and is domiciled in Canada. Read Less
Big Pharma Split Corp is a closed ended equity mutual fund launched and managed by Harvest Portfolios Group Inc. It invests in the public equity markets across United States. The fund primarily invests in the Pharmaceutical sector. Big Pharma Split Corp was formed on September 15...Read More
Frequently Asked Questions About Big Pharma Split Corp Class A (PRM:CA) Stock
Stock Target Advisor's fundamental analysis for Big Pharma Split Corp Class A's stock is Slightly Bearish.
PRM:CA stock's dividend yield is 8.81%.
Our analysis grades PRM:CA stock's dividend yield at D. This means that PRM:CA stock's dividend yield is above 65% of the stocks in the Asset Management sector in the TSX exchange.
Based on this PRM:CA may be a average dividend stock for its sector.
Unfortunately we do not have enough data on PRM:CA's stock to indicate what its average analyst target is.
PRM:CA stock's Price/Earning ratio is 9.48.
Our analysis grades PRM:CA stock's Price / Earning ratio at F. This means that PRM:CA stock's Price/Earning ratio is above 53% of the stocks in the Asset Management sector in the TSX exchange.
Based on this PRM:CA may be a overvalued for its sector.
The last closing price of PRM:CA's stock was CAD 14.97.
The most recent market capitalization for PRM:CA is CAD 0.02B.
Unfortunately we do not have enough analyst data on PRM:CA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Big Pharma Split Corp Class A's stock.
As per our most recent records Big Pharma Split Corp Class A has 0 Employees.
Big Pharma Split Corp Class A's registered address is 610 Chartwell Road, Oakville, ON, Canada, L6j 4A5.
You can get more information about it from Big Pharma Split Corp Class A's website at https://www.harvestportfolios.com/closed-end-funds.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Superior total returns
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PRM:CA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
